Figure 5

Chemical LSD1 inhibitors reduce the cell viability of a panel of ovarian cancer cell lines. (A) Western blot analysis of LSD1 protein levels in a panel of human ovarian cancer lines (SKOV3, OVCAR-3, A2780, and the cisplatin-tolerant derivative A2780cis). We show also analysis of LSD1 protein expression in two positive controls: breast cancer MCF7 cells and prostate cancer LNCaP cells. (B) Chemical structure of non-selective LSD1 inhibitor tranylcypromine (TCP or 2-PCPA). (C) Representative bright-field microscopy images of SKOV3 cells treated with LSD1 inhibitor TCP for the time labeled on top of the panels. Magnification x10. Bar = 50 μm. (D) Western blot analysis of PARP1 cleavage (note: cleaved fragment corresponds to the band of faster migration), and LSD1 substrate H3K4me2 in SKOV3 cell treated with increasing amounts of LSD1 inhibitor TCP. (E) Chemical structure of non-selective LSD1 inhibitors: pargyline, RN-1, and S2101. (F) Estimated IC50 values and 95% CI for each LSD1 inhibitor in our panel of ovarian cancer lines (extracted from the graphs shown in Additional file 8: Figure S6B-S6E). The y-axis is log-10 scale. (G) Estimated IC50 values and 95% CI for each LSD1 inhibitor in breast cancer MCF7 cells. The y-axis is log-10 scale.